About

Inzit™ – The only triple calcium channel blocker

Among CCB class, Inzit™ provides

Superior BP Reduction

Superior CV Protection

Superior Renal protection

Inzit™ a novel Calcium channel blocker which improve clinical outcome in hypertension.

Inzit™ is a novel Calcium channel blocker approved for use in hypertension & angina pectoris.

Inzit™ is the only CCB which block L, N and T-type calcium channels. Mostly all the currently available CCB, block L-type or L/N type calcium channels. Due to its unique triple Ca+2 channels blocking action it has superior BP reduction, cardio protection & Renoprotection benefits as compared to other CCBs.

Additionally the other CCBs have a severe adverse effect profile which mainly includes – Pedal Edema. This traditional limitation of CCBs producing pedal edema is overcome by Inzit™. The incidences of pedal edema with Inzit™ have been reported to be around 0.5%.

Calcium channel blockers (CCBs) are a class of medications used to treat high blood pressure. Currently available CCB, block L-type or L/N type calcium channel. Inzit™ is the only CCB which block L, N and T-type calcium channels. Also, the traditional limitation of CCB producing pedal oedema is overcome with Inzit™. It is reported that, Inzit™ has only 0.5% incidence of pedal oedema.

Inzit™ is a prescription drug, currently available for sale in India only.

Launched by Eris Lifesciences in January 2017, Inzit™ is a best-in-class molecule which have a unique mechanism of action. The molecule Benidipine has shown beneficial effects on cardiovascular protection and renal protection.

Characteristics of Benidipine

Greater binding affinity

The Ki value of benidipine for the DHP binding site is 0.08 – 0.13 nmol/L, which indicates that this drug has a higher affinity for the DHP binding site than nisoldipine, nicardipine,nitrendipine, verapamil, and diltiazem.

Slow binding to receptor

Nitrendipine took 20 min to reach equilibrium, while benidipine took 180 min to reach equilibrium, indicating that the binding of benidipine is very slow.

Slow dissociation from receptor

Dissociation rate determined by the addition of nitrendipine after the binding of each drug with rat heart membranes, the slope of the dissociation curve was much lower for benidipine than for nifedipine, indicating that dissociation of benidipine takes place very slowly.

High lipophilicity

The log P of benidipine, Nifedipine & Amlodipine was 4.61, 2.20 & 3.95 indicating the very high lipophilicity of Benidipine compared with Nifedipine and Amlodipine.

Approved indication

  • Hypertension
  • CKD with hypertension patient
  • Renal parenchymal hypertension
  • Diabetic nephropathy
  • Long-term prophylactic management of angina pectoris